10,102 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC bought a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,102 shares of the company’s stock, valued at approximately $1,646,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pensionfund Sabic raised its stake in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares during the last quarter. PFW Advisors LLC purchased a new position in shares of Zoetis during the 4th quarter valued at about $1,764,000. JPMorgan Chase & Co. raised its stake in shares of Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Zoetis during the 3rd quarter valued at about $11,684,000. Finally, Nordea Investment Management AB raised its stake in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after buying an additional 572,511 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.2 %

ZTS stock opened at $171.71 on Tuesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The stock has a market cap of $77.47 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.77 and a beta of 0.90. The business’s 50-day moving average is $169.26 and its 200 day moving average is $179.21.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Analysts Set New Price Targets

ZTS has been the subject of a number of recent research reports. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.